Levolin INHALER

Quick links to important sections

Levolin INHALER

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Levolin INHALER

Quick Facts

Property Description
Active Ingredient Levosalbutamol (Levalbuterol)
Form Metered-Dose Inhaler (MDI)
Pharmacological Class Short-Acting Beta-Agonist (SABA)
Common Use Rapid relief of breathing difficulty (bronchospasm)
Origin Synthetic (Purified component of Salbutamol)

What Type of Medicine is Levolin Inhaler? (Class and Definition)

Levolin Inhaler is a brand-name pharmaceutical product containing the active ingredient levosalbutamol (also known as levalbuterol), which is classified as a Short-Acting Beta-Agonist (SABA) bronchodilator. This class of medicine is specifically used for the rapid, acute relief of airway constriction.

The drug levosalbutamol is the purified, therapeutically active component of the older, racemic drug salbutamol (albuterol). This formulation is designed to provide relief of acute symptoms. Levolin is typically designated as a Prescription-Only Medicine (Rx), intended for use under professional medical guidance.

Composition and Delivery Form (Ingredients and Physical State)

Levolin is supplied as a Metered-Dose Inhaler (MDI), a pressurized device that ensures a precise, measured dose of levosalbutamol is administered as an aerosol mist directly to the airways. The active ingredient is formulated alongside specific non-active components and a propellant necessary for the device's function.

The direct inhalation route provides swift relief at the site of constriction. Levolin is utilized for its delivery across different patient populations, including children and adults.

What is the General Therapeutic Purpose? (High-Level Benefit)

The general therapeutic purpose of Levolin Inhaler is to function as a rescue medication for the on-demand treatment of bronchospasm. Its overall goal is to quickly open up narrowed air passages to restore normal breathing function. A typical use scenario involves a patient experiencing a sudden flare-up of symptoms, such as acute wheezing or tightness in the chest, where prompt intervention is necessary.

What side effects are possible with Levolin INHALER?

Possible side effects and safety information

The safety profile of Levolin Inhaler (levosalbutamol) is based on adverse reactions observed during clinical studies and post-marketing surveillance, as documented by regulatory authorities. Side effects are formally classified by frequency and the physiological system affected.


Documented Adverse Reactions

The most frequently observed adverse reactions, classified as Common in regulatory labeling (events in ge 2% of patients and greater than placebo), often involve the nervous and cardiovascular systems. These include Headache, Dizziness, Tremor, and Nervousness. Other Common effects are Tachycardia (increased heart rate), Chest Pain, Pharyngitis (sore throat), Rhinitis, Sinusitis, Vomiting, and Dyspepsia (indigestion).

System-Organ Class Examples of Common Adverse Reactions
Nervous System Disorders Headache, Tremor, Nervousness, Dizziness
Cardiac/Vascular Disorders Tachycardia, Chest Pain
Infections and Infestations Pharyngitis, Rhinitis, Sinusitis
Gastrointestinal Disorders Vomiting, Dyspepsia

Serious Safety Considerations

The official labeling documents several clinically significant safety concerns. The most critical is the potential for Paradoxical Bronchospasm, which is a sudden, severe, and potentially life-threatening worsening of breathing that may occur immediately following inhalation. Other serious adverse reactions include severe Immediate Hypersensitivity Reactions (such as Angioedema or Anaphylaxis) and significant Cardiovascular Effects.


Safety Restrictions and Warnings

Specific cautions are outlined for use in certain populations and with other medications. Levolin should be used with mandatory caution in patients with underlying Cardiovascular Disorders (Coronary Insufficiency, Hypertension), Hyperthyroidism, Convulsive Disorders, or Diabetes Mellitus. The use of non-selective Beta-Blockers is contraindicated as they may severely worsen breathing and negate the intended bronchodilatory effect. Furthermore, the medicine is associated with documented Metabolic Changes, including a potential for transient Hypokalemia (low serum potassium).

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for Levolin INHALER (levosalbutamol) is defined by the exaggeration of its pharmacological effects, reflecting excessive beta2-adrenergic stimulation as documented in regulatory sources.

Documented Overdose Manifestations

System Officially Listed Signs/Symptoms
Cardiovascular Tachycardia (fast or pounding heart rate), palpitations, hypertension, and hypotension.
Neurological Severe tremor, nervousness, headache, and seizures are documented.
Metabolic Overdose is associated with critical findings, including hypokalemia (low potassium) and lactic acidosis, which may lead to metabolic acidosis.

Required Emergency Actions

In cases of suspected overdose, regulatory guidance mandates immediate action due to the potential for serious outcomes, including fatalities and cardiac arrest associated with the excessive use of inhaled sympathomimetic agents.

Immediate medical help must be sought if severe symptoms such as collapse, seizure, or profound trouble breathing occur. The official guidance requires contacting emergency services (e.g., 911) or a Poison Control Helpline.

Management focuses on discontinuing the medicine and providing appropriate symptomatic and supportive therapy. A cardioselective beta-receptor blocker may be considered, but must be used judiciously due to the risk of precipitating bronchospasm. Monitoring of ECG and serum potassium levels is required for management.

Therapeutic Uses of Levolin INHALER

Quick Facts: Levolin INHALER Uses

  • Main Therapeutic Domain: Management of symptoms related to reversible obstructive airway disease.
  • Key Benefits: Helps relieve and prevent episodes of bronchospasm.
  • Conditions Addressed: Associated with conditions such as asthma and chronic obstructive pulmonary disease (COPD).

What Levolin INHALER treats: main uses and benefits

Levolin INHALER (containing levosalbutamol) is a therapeutic compound indicated for the management of respiratory conditions that involve the narrowing of airways. Its primary therapeutic role is in the treatment and prevention of bronchospasm—a constriction of the muscles surrounding the airways—in individuals who have reversible obstructive airway disease. This includes patients diagnosed with asthma and chronic obstructive pulmonary disease (COPD).

Use of the compound may assist in addressing symptoms such as wheezing, coughing, and difficulty in breathing. By helping to relax the bronchial muscles, the compound supports the improvement of airflow in the lungs. This action facilitates relief from acute respiratory discomfort, making it a component of a patient's treatment regimen as determined by a healthcare professional.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Levolin INHALER

Contraindications

The medicine is absolutely contraindicated (must not be used) in patients with a history of hypersensitivity (allergic reactions) to levosalbutamol (levalbuterol), racemic albuterol, or any other component of the inhaler product, as stated in regulatory labeling.


Age-Related Eligibility

Age Group Regulatory Status
Adults and Adolescents (≥ 12 years) Approved for use
Children (4 to 11 years) Approved for use
Children (< 4 years) Safety and efficacy are not established (use not established)
Geriatric Patients (≥ 65 years) Use with caution

Condition-Specific Eligibility Restrictions

Use of Levolin INHALER requires caution in patients with specific underlying conditions, as its use can affect these systems. These conditions include cardiovascular disorders (such as hypertension or cardiac arrhythmias), diabetes mellitus, hyperthyroidism (overactive thyroid), and convulsive disorders.

Renal Impairment also requires caution, especially with high doses, due to the potential for reduced drug clearance. No specific restrictions are typically listed in regulatory labels for hepatic (liver) impairment.


Pregnancy and Lactation Eligibility

Official labeling indicates that use during pregnancy is assigned to FDA Category C, meaning it should only be used if the potential benefit justifies the potential risk. For lactation (breastfeeding), it is not known if the drug is excreted in human milk, and caution is advised.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Levolin INHALER (levosalbutamol/levalbuterol) is a Short-Acting Beta-Agonist (SABA) whose official interaction profile is defined by pharmacodynamic effects, as documented by regulatory authorities. The primary concern is the potentiation of cardiovascular effects and the risk of antagonism of the intended therapeutic action.


Documented Pharmacodynamic Interactions

Co-administration with Beta-adrenergic receptor blocking agents may lead to Pharmacodynamic Antagonism, which blocks the intended bronchodilatory effect and carries the risk of inducing severe bronchospasm. Conversely, combining levosalbutamol with other adrenergic drugs, Monoamine Oxidase Inhibitors (MAOIs), or Tricyclic Antidepressants (TCAs) may result in Additive Cardiovascular Stimulation, potentially potentiating effects on the heart and circulation.


Other Clinically Significant Interactions

Interacting Agent Official Interaction Outcome Timing Restriction
Other Sympathomimetic Aerosols Additive cardiovascular effects. Should not be used concomitantly.
Non-potassium-sparing Diuretics May acutely worsen hypokalemia and ECG changes. None stated.
Digoxin May result in a decrease in serum levels of Digoxin. None stated.

All interaction-related constraints reflect official regulatory statements and are based on the documented outcomes between levosalbutamol and these substance classes.

Mechanism of Action

️ How Levolin INHALER Works

Levolin Inhaler contains the pure (R)-enantiomer of salbutamol (levosalbutamol), which possesses high affinity for its intended biological target. The drug's mechanism is defined by a molecular cascade that modulates the involuntary tone of airway smooth muscles.

Molecular Agonism at the mathbfbeta2-Adrenergic Receptor

The mechanism begins as levosalbutamol acts as a full agonist at the Beta-2 Adrenergic Receptor (beta2-AR), the primary target located on the surface of airway smooth muscle cells. This interaction initiates a critical signal transduction cascade within the cell, mimicking the effect of the body’s sympathetic nervous system in modulating muscle tone.

Activation of the Intracellular cAMP Signaling Pathway

Binding to the beta2-AR leads to the activation of Adenyl Cyclase, which converts ATP into the second messenger cyclic AMP (cAMP). The subsequent increase in cAMP levels activates Protein Kinase A (PKA), which is the key enzyme responsible for inhibiting the biochemical processes required for smooth muscle contraction and modulating the release of mediators from certain cells.

Physiological Consequence: Airway Smooth Muscle Relaxation

The PKA-mediated cascade effectively lowers intracellular ionic calcium (Ca^2+) levels and disrupts the molecular machinery responsible for muscle shortening. The resulting physiological effect is the relaxation of bronchial smooth muscle (bronchodilation), which physically increases the diameter of the air passages.

Dosage and Administration Information

How Levolin INHALER is Used: Administration Guidelines

Levolin INHALER (levosalbutamol/levalbuterol) is administered exclusively via oral inhalation using a pressurized Metered-Dose Inhaler (MDI). Its usage follows a protocol regarding dosing frequency, age-specific administration, and device handling.


Dosing and Frequency

The standard dose for adults and children aged 4 years and older is 2 inhalations (a total of 90 mcg of levosalbutamol) per dose.

Usage Context Dosing Regimen Frequency / Timing
Symptomatic Relief (Acute Use) 2 inhalations (90 mcg) Repeat dose every 4 to 6 hours as needed
Prevention of Exercise-Induced Bronchospasm (EIB) 2 inhalations (90 mcg) Take 15 to 30 minutes before exercise

Administration Requirements

Adherence to preparation and use guidelines is necessary to ensure the correct dose is delivered:

  • Priming: The MDI must be primed before the first use, or if it has not been used for more than three days. Priming involves releasing 4 test sprays into the air.
  • Shaking: The inhaler must be shaken well immediately before each dose administration.
  • Cleaning: The actuator (mouthpiece) should be cleaned at least once per week by washing it with warm water and allowing it to air-dry completely.

High-Level Use Constraints

The need for more frequent use of the inhaler than the standard regimen may indicate a change in the patient's underlying condition and warrants an evaluation by a healthcare provider. The product is not approved for use in pediatric patients under 4 years of age.

Recent Clinical Evidence

Levolin INHALER: Recent Clinical Evidence


Research Scope and Findings

Research has explored the potential of levosalbutamol (Levolin INHALER) in managing respiratory conditions, particularly those involving bronchospasm. Studies evaluated the compound's characteristics, focusing on its mechanism as a selective beta-2 adrenergic agonist.

Summary of Clinical Findings

Clinical trials have evaluated the effect of levosalbutamol on lung function, primarily assessing changes in the forced expiratory volume in one second (FEV1), a standard measure of airway obstruction relief. Trials compared levosalbutamol to placebo and to racemic albuterol, the mixture containing both R- and S-isomers.

Efficacy and Outcome Assessment

  • Phase III Trials: Large-scale, double-blind, placebo-controlled trials enrolled participants with asthma and chronic obstructive pulmonary disease (COPD). The trials examined whether the levosalbutamol group reported a greater increase in FEV1 from baseline compared to the placebo group. Findings indicated an observed increase in mean FEV1 within minutes of administration in multiple studies.
  • Comparative Research: Some research explored differences in bronchodilator efficacy compared to racemic albuterol. These studies focused on achieving comparable FEV1 improvement using a lower dose of levosalbutamol.

Tolerability and Safety Profile

Reported adverse events were generally mild and transient, primarily including tremor and headache. Because levosalbutamol contains only the R-isomer, which is responsible for the desired bronchodilator effect, studies were conducted to determine if its use resulted in fewer side effects, such as tachycardia, compared to racemic albuterol. The findings regarding this comparative side effect profile remain varied across published literature.

Frequently Asked Questions (FAQ)

Common questions about Levolin INHALER (FAQ)


Q: How quickly does Levolin INHALER start working after one puff?

Studies summarized in official product information indicate that an increase in measured lung function (FEV1) is observed within minutes of administration. The onset of peak measured effect can vary slightly among individuals.


Q: Is the active ingredient in Levolin INHALER different from the one in Ventolin or Asthalin?

Yes, Levolin INHALER contains levosalbutamol, which is the purified, therapeutically active component of the older drug salbutamol (also known as albuterol, the active ingredient in drugs like Ventolin or Asthalin). This means Levolin contains only the specific part of the molecule responsible for the intended bronchodilator effect.


Q: Why might a doctor prescribe Levolin INHALER instead of a standard albuterol inhaler?

Research comparing levosalbutamol to racemic albuterol has focused on achieving comparable improvement in lung function, often at a lower dosage. These studies explored whether the pure R-isomer could achieve comparable efficacy while potentially reducing the common side effects associated with the racemic mixture, such as tachycardia (increased heart rate), though findings on this are varied.


Q: What should I check for if my Levolin INHALER doesn't seem to be working well?

Official guidelines emphasize that if the inhaler fails to provide the usual response, it may be a sign of destabilization of asthma and requires reevaluation. Regulatory guidelines also detail the importance of following administration instructions, including proper priming and shaking before each use.


Q: How long can the effects of Levolin INHALER last?

The official product information specifies that the action of the medicine is officially described as lasting for approximately 4 to 6 hours. The regulatory label indicates that a change in condition may be present if relief is needed more frequently than the regimen allows.


Q: Is Levolin INHALER a steroid or does it contain corticosteroids?

No. Official regulatory documents clarify that this medicine is a Short-Acting Beta-Agonist (SABA) bronchodilator and is explicitly not a substitute for corticosteroids (anti-inflammatory agents). These anti-inflammatory medicines are often used to treat the underlying inflammation in the airways.


Q: Are there any long-term side effects associated with using Levolin INHALER regularly for many years?

Long-term clinical trials of up to 52 weeks have been conducted to assess safety with regular use. These studies indicated that the product was generally well tolerated and no deterioration of lung function was observed during the study period. Information regarding the use of the medicine for durations longer than those studied is not available in the official labeling.


Q: Is Levolin INHALER known to interact with caffeine or energy drinks?

Regulatory documents do not list specific interactions with common beverages, but they do caution against using Levolin with other adrenergic drugs. Combining these substances with Levolin may potentiate cardiovascular effects due to additive stimulation on the heart and circulation.


Q: Is there a way to check how many doses (puffs) are left in the Levolin INHALER canister?

The product is supplied in canisters that contain a specific number of metered actuations (doses). Official information confirms that the device may include a dose indicator display to help track the number of puffs remaining, and the device should be discarded when this indicator reaches zero.


Q: Is the Levolin INHALER considered a 'habit-forming' medicine?

Official labeling includes a warning that abuse of sympathomimetic medications, such as the active ingredient in Levolin, may be associated with serious adverse cardiac events including cardiac arrest and death.


Q: Does Levolin INHALER interact with any common over-the-counter cold or allergy medicines?

Regulatory warnings state that combining Levolin with other adrenergic drugs may result in additive cardiovascular stimulation. The regulatory warning cautions that combining Levolin with other adrenergic drugs may result in additive cardiovascular stimulation.


Q: What is the difference between a Levolin INHALER and Levolin solution used in a nebulizer?

Levolin is available in two forms, both containing the active ingredient levosalbutamol. The INHALER is a pressurized Metered-Dose Inhaler (MDI), while the solution is specifically intended for use with a nebulizer device. The choice of delivery system is based on individual patient need.


Q: Are there any specific foods or drinks to avoid while using Levolin INHALER?

Regulatory warnings for this medication focus primarily on drug-drug interactions with specific classes of medicines. The warnings generally caution against co-administration with other substances that significantly affect the cardiovascular system, but specific restrictions on food or drinks are not listed in the official labeling.


Q: Does the propellant in Levolin INHALER affect the environment (climate change concerns)?

The official product description confirms that this inhaler uses Propellant HFA-134a (hydrofluoroalkane). Importantly, the device does not contain chlorofluorocarbons (CFCs) (an older type of propellant), which were phased out due to environmental concerns.


Q: Can Levolin INHALER affect a person's ability to drive or operate machinery?

Official labeling notes that common adverse reactions include effects like Dizziness and Tremor. The presence of these effects is noted in official labeling, and these effects may potentially impair the ability to perform tasks like driving or operating complex machinery.


Q: What should I be aware of if I also take a preventative (controller) inhaler alongside Levolin INHALER?

Official labeling notes that if the patient’s asthma deteriorates, reevaluation is required. A specific consideration in this scenario is the possible need for adjustments to the anti-inflammatory treatment, such as the preventative (controller) medication being used.


Q: Does Levolin INHALER help with lung inflammation?

According to the official product information, this medicine works as a bronchodilator to open the airways, but it is not a substitute for anti-inflammatory agents (like inhaled corticosteroids) that treat lung inflammation. Inflammation treatment often requires a separate, controller medication.


Q: Why is it important to synchronize breathing with pressing the canister when using an MDI like Levolin?

The official Instructions for Use detail the proper method for inhalation. The instructions for use detail the proper inhalation method to ensure a consistent inspiratory flow rate and duration are maintained, which is critical for delivering the correct dose of medicine to the airways.


Q: Does the effectiveness of Levolin INHALER diminish over time with prolonged use?

The official labeling includes a warning that if a previously effective dosage regimen fails to provide the usual response, this may be a sign of destabilization of asthma. The label notes that a failure to provide the usual response may be a sign of destabilization of asthma, for which reevaluation is required.

How should Levolin INHALER be stored and disposed of?

Storage Conditions and Disposal Rules

Levolin (levalbuterol tartrate) inhalation aerosol must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). It must be protected from freezing, excessive heat, and direct sunlight. Due to the canister's pressurized contents, storage temperatures must never exceed 49 C (120 F), and the container must not be punctured or disposed of in an incinerator.

The inhaler must be kept out of the sight and reach of children.

Disposal

The device must be discarded when the dose indicator display window shows zero, regardless of perceived remaining content. Do not throw the used canister into a fire. Follow local laws and contact the local trash and recycling facility for guidance on the proper disposal of pressurized aerosol containers.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Levolin INHALER found in:

A-Z Index: